Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.74 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616938 | 0.96 | NLRP3 (0.69) | NLRP3FBP1CA12CA1CA2 | |
| SCHEMBL7612024 | 0.96 | NLRP3 (0.69) | NLRP3FBP1CA12CA1CA2 | |
| SCHEMBL7614656 | 0.93 | NLRP3 (0.65) | NLRP3FBP1CA12CA1CA2 | |
| SCHEMBL7621810 | 0.93 | NLRP3 (0.68) | NLRP3FBP1CA12CA1CA2 | |
| SCHEMBL7617403 | 0.92 | NLRP3 (0.66) | NLRP3FBP1CA12CA1CA2 | |
| SCHEMBL7617355 | 0.91 | NLRP3 (0.63) | NLRP3FBP1CA12CA1CA2 | |
| SCHEMBL7140501 | 0.90 | NLRP3 (0.75) | NLRP3CA12CA1CA2CA9 | |
| SCHEMBL6555763 | 0.89 | NLRP3 (0.76) | NLRP3FBP1 | |
| SCHEMBL7137330 | 0.89 | NLRP3 (0.76) | NLRP3FBP1 | |
| SCHEMBL7613905 | 0.89 | NLRP3 (0.61) | NLRP3FBP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0964849-B1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1270554-A1 | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1270565-A1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6433009-B1 | TREATMENT OF AUTOIMMUNE, CARDIOVASCULAR, NERVOUS SYSTEM, GASTROINTESTINAL, RESPIRATORY SYSTEM, AND VIRAL DISORDERS; ANTIDIABETIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANTIDEPRESSANT AGENTS | PFIZER INC | 2002-08-13 | — | — | US | disclosed |
| EP-1214087-A1 | COMBINATION TREATMENT WITH IL-1RA AND COMPOUNDS THAT INHIBIT IL-1 PROCESSING AND RELEASE | Pfizer Products Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019390-A1 | COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |